OTCMKTS:OPHLF Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free OPHLF Stock Alerts $16.64 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$16.64▼$16.6450-Day Range$16.01▼$17.6952-Week Range$16.01▼$20.97Volume2,900 shsAverage Volume1,155 shsMarket CapitalizationN/AP/E Ratio8.99Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Ono Pharmaceutical alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Ono Pharmaceutical Stock (OTCMKTS:OPHLF)Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; and a research collaboration with Turbine Ltd. to identify and validate novel oncology targets. The company was founded in 1717 and is headquartered in Osaka, Japan.Read More OPHLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPHLF Stock News HeadlinesMarch 14, 2024 | msn.comDon Lemon Says His Talk Show Deal with X Was Canceled After Tense Interview with Elon Musk: 'He's Mad at Me'February 24, 2024 | msn.comOno Pharmaceutical Co., - Depositary Receipt () (OPHLY) Price Target Increased by 19.99% to 7.80March 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: February 22, 2024 | finance.yahoo.comOno Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic TargetsFebruary 20, 2024 | msn.comLondon exhibition celebrates 'unknown artist' Yoko OnoFebruary 14, 2024 | uk.finance.yahoo.comOno Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsFebruary 14, 2024 | globenewswire.comNumab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of CancerFebruary 5, 2024 | msn.comNVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?March 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 5, 2024 | investing.comOno Pharmaceutical Ltd (4528)January 16, 2024 | seekingalpha.comODP: A Value Play With CatalystsJanuary 16, 2024 | wsj.comSnack Maker Orion Slumps After Pharma Acquisition PushDecember 21, 2023 | tmcnet.comOno Enters into Research Collaboration with UK Dementia Research InstituteDecember 19, 2023 | markets.businessinsider.comBioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer ResearchDecember 16, 2023 | msn.comOno Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 29.83% to 7.51December 9, 2023 | seekingalpha.comORIC Pharma NSCLC Brain Metastasis Data Is Highly InterestingDecember 1, 2023 | finance.yahoo.comOno Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 MillionNovember 28, 2023 | finance.yahoo.comU.S. Stocks Open Mostly Lower, With S&P 500 Falling Slightly Ahead Of Fed SpeakersNovember 28, 2023 | finance.yahoo.comNikkei Edges Lower on Yen Strength, Likely Position AdjustmentNovember 27, 2023 | finance.yahoo.comNikkei Falls 0.4% Amid JPY StrengthNovember 1, 2023 | msn.comOzempic, Wegovy demand drives up illegal sales of weight-loss drugsOctober 28, 2023 | morningstar.comOno Pharmaceutical Co LtdSeptember 1, 2023 | finance.yahoo.comOno Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's WhyJuly 30, 2023 | markets.businessinsider.comONO PHARMACEUTICAL is about to announce earnings — here's what Wall Street expectsJanuary 27, 2023 | msn.comUSFDA gives exception to Glenmark Pharma to supply pneumonia drug from Baddi facilityDecember 15, 2022 | technews.tmcnet.comPrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono PharmaceuticalDecember 14, 2022 | msn.comPrecisionLife and Ono Pharmaceutical enter multi-year collaborationSee More Headlines Receive OPHLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings1/31/2024Today3/19/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OPHLF CUSIPN/A CIK940821 Webwww.ono.co.jp Phone(166) 263-5670Fax816-6263-2950Employees3,761Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.85 Trailing P/E Ratio8.99 Forward P/E Ratio8.85 P/E GrowthN/ANet Income$834.15 million Net Margins25.43% Pretax MarginN/A Return on Equity16.32% Return on Assets14.16% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio3.04 Sales & Book Value Annual Sales$3.31 billion Price / SalesN/A Cash Flow$1.87 per share Price / Cash Flow8.88 Book Value$10.76 per share Price / Book1.55Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.63 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Gyo Sagara (Age 66)CEO, President & Representative Director Comp: $917.76kMr. Masaki ItoCorp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. TaxTakehiro YamadaCorporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion OfficeMasayuki TanigawaCorporate Officer & Executive Director of Corporate Development & StrategyMr. Toichi Takino Ph.D. (Age 56)Senior Managing Executive Officer, Head of Research Division & Director Mr. Toshihiro Tsujinaka (Age 60)Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director Hiromu Habashita Ph.D.Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of ImmunologyKiyoaki Idemitsu (Age 60)Managing Executive Officer, GM of Development Division & Director Shinji Takai M.D.Ph.D., Corporate Officer & Head of Medical AffairsSatoshi TakahagiCorporate Officer and Executive Director of Sales, Marketing & Primary Care Business DivisionMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSADC TherapeuticsNYSE:ADCTAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSView All Competitors OPHLF Stock Analysis - Frequently Asked Questions How have OPHLF shares performed in 2024? Ono Pharmaceutical's stock was trading at $17.6850 at the beginning of 2024. Since then, OPHLF stock has decreased by 5.9% and is now trading at $16.64. View the best growth stocks for 2024 here. Are investors shorting Ono Pharmaceutical? Ono Pharmaceutical saw a increase in short interest in February. As of February 15th, there was short interest totaling 3,251,200 shares, an increase of 31.4% from the January 31st total of 2,474,600 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 32,512.0 days. View Ono Pharmaceutical's Short Interest. How were Ono Pharmaceutical's earnings last quarter? Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) released its quarterly earnings data on Wednesday, January, 31st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.06. The company had revenue of $888.42 million for the quarter. Ono Pharmaceutical had a trailing twelve-month return on equity of 16.32% and a net margin of 25.43%. How do I buy shares of Ono Pharmaceutical? Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OPHLF) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.